UNAIDS commends Merck’s decision to register ATRIPLA in developing countries. The registration of ATRIPLA, a once-daily single tablet regimen for treatment of HIV infection in adults, exemplifies the joint efforts of two research and development leaders, Merck Co. and Gilead Sciences to make essential medicines available to those in need.